PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 25, 2016Journal of Clinical Oncology359 citationsOpen Access

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

SASergio AmadoriSSStefan SuciuDSDominik Selleslag

Key Points

Key points are not available for this paper at this time.

Abstract

First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Amadori et al. (2016) studied this question.

synapsesocial.com/papers/69dd28810a7b4bc8c4100e1ahttps://doi.org/10.1200/jco.2015.64.0060
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison2012 · 160 citations
  2. 2Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials2014 · 710 citations
  3. 3Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival2013 · 131 citations
  4. 4Management of older or unfit patients with acute myeloid leukemia2014 · 92 citations
  5. 5Gemtuzumab Ozogamicin: Time to Resurrect?2012 · 106 citations